National Public Radio: Morning Edition | Peter Granitz & Rob Stein
“Having a safe and effective vaccine available for children in this age group is a priority for the agency and we’re committed to a timely review of the data.”
Granitz and Stein discuss a new vaccine regimen for children between six months to five years old from Pfizer-BioNTech. The new protocol could be authorized for emergency use by the FDA much earlier than anticipated.
